Clinical trials: Cyclophosphamide, completed
MRD-positive, Acute Lymphoblastic Leukemia
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
To evaluate the safety and efficacy of CD19/CD22 Bispecific chimeric antigen receptor (CAR)-T for the treatment of measurable residual disaese (MRD)-positive B cell acute lymphoblastic leukemia.
- Trial name
- NCT03919526
- Testing
- anti-CD19/CD22 CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Double Expressor Lymphoma
Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients
In this phase II study, the investigators are aiming to explore lenalidomide combined with R-CHOP (R2-CHOP) in newly diagnosed double-expressor Diffuse Large B-Cell Lymphoma patients (DLBCL)
- Trial name
- NCT04164368
- Testing
- Lenalidomide combined with R-CHOP
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Fudan University
Breast Cancer
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
CMF (cyclophosphamide, methotrexate, fluorouracil) is used to treat early stage breast cancer. The combination, of these three drugs, has been used for approximately 30 years in the treatment of breast cancer, and has been shown…
- Trial name
- NCT00615901
- Testing
- cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia
Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003764
- Testing
- cyclophosphamide, fludarabine phosphate
- Where
- 218 sites in United States, Canada and 2 more
- Volunteers
- 280 people
- Sponsor
- Eastern Cooperative Oncology Group
Lymphoma
Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00039351
- Testing
- cyclophosphamide, prednisone, vincristine sulfate
- Where
- 17 sites in Belgium, Egypt and 5 more
- Volunteers
- 32 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer
This is an open randomized phase III study. The primary objective of this study is to compare FEC adjuvant chemotherapy in operable breast cancer given either as fixed doses calculated according to the patients surface area or…
- Trial name
- NCT03888677
- Testing
- 5-FU, epirubicin and cyclophosphamide
- Volunteers
- 1,535 people
- Sponsor
- Henrik Lindman
HER2 Positive Breast Carcinoma, Stage I Breast Cancer AJCC v7
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
This phase II trial studies the side effects and how well cyclophosphamide, paclitaxel, and trastuzumab work when given after surgery in treating patients with stage I-II human epidermal growth factor receptor (HER2/neu) positive…
- Conditions
- HER2 Positive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
- Trial name
- NCT02654119
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Nebraska
Breast Cancer
Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
This is a prospective, multicenter, open label, non-comparative trial in Spain. The primary objective of this study is to determine the complete response, defined as no vomiting and no use of rescue treatment, in women with…
- Trial name
- NCT01298193
- Testing
- Aprepitant
- Where
- 13 sites in Spain
- Volunteers
- 212 people
- Sponsor
- Spanish Breast Cancer Research Group
Neuroblastoma
Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00025597
- Testing
- carboplatin, cyclophosphamide, doxorubicin hydrochloride
- Where
- 11 sites in Austria, Belgium and 9 more
- Sponsor
- European Infant Neuroblastoma Study Group - 1999
T-cell Lymphoma, Leukaemia
High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
Patients are recruited at diagnosis or at relapse of ATLL-HR in French Caribbean islands and Guyana. They all receive Zidovudine and Pegylated Interferon (ZPI).
- Trial name
- ATLL-HR-01 (NCT01941680)
- Where
- 2 sites in Guadeloupe, Martinique
- Volunteers
- 20 people
- Sponsor
- University Hospital Center of Martinique
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
This is a phase I study of temsirolimus (Torisel) combined with dexamethasone, cyclophosphamide and etoposide in patients with relapsed acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) or peripheral T-cell lymphoma…
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
- Trial name
- NCT01614197
- Testing
- Temsirolimus, Etoposide, Cyclophosphamide
- Where
- 32 sites in United States, Australia and 1 more
- Volunteers
- 16 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Idiopathic Membranous Nephropathy
Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy
The purpose of this study is: To explore the potential role of tacrolimus in the treatment of membranous nephropathy. To investigate the safety and tolerability of tacrolimus vs methylprednisolone plus cyclophosphamide.
- Trial name
- NCT00302523
- Testing
- Tacrolimus
- Where
- 2 sites in China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nanjing University School of Medicine
Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, in Relapse
Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children
The investigators will conduct a phase II clinical trial of autologous murine anti-CD19 chimeric antigen receptor T cells treating refractory or relapsed B acute lymphoblastic leukemia children in Beijing Boren Hospital.
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT04325841
- Testing
- Murine autologous anti-CD19 chimeric antigen receptor T cells
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Beijing Boren Hospital
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.
This phase II trial studies how well combination chemotherapy with or without bortezomib works in treating patients with classical Hodgkin lymphoma that has come back or does not respond to prior treatment.
- Trial name
- NCT00967369
- Testing
- Bortezomib, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Nephrotic Syndrome
A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome
To demonstrate that the treatment effect in refractory nephrotic syndrome of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.
- Trial name
- NCT02257697
- Testing
- Mizoribine (MZR), Cyclophosphamide (CTX)
- Where
- 28 sites in China
- Volunteers
- 239 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Neuroendocrine Tumors
Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors
This study will evaluate the potential immunomodulatory synergy of the association of metronomic cyclophosphamide (CMC) and interferon-alpha (IFN-alpha).
- Trial name
- EPICentro (NCT02838342)
- Testing
- Metronomic cyclophosphamide, Interferon-alpha
- Where
- 2 sites in France
- Volunteers
- 28 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Metastatic Prostate Cancer, Cancer of the Prostate
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
This clinical trial will examine a novel combination of anti-OX40 to induce proliferation of memory and effector T cells in conjunction with cyclophosphamide (CTX) and radiation to induce tumor antigen release with the overall…
- Conditions
- Metastatic Prostate Cancer, Cancer of the Prostate, Prostate Cancer
- Trial name
- NCT01303705
- Testing
- Anti-OX40, Radiation, Cyclophosphamide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Providence Health & Services
Sarcoma
Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002546
- Testing
- cisplatin, ifosfamide, adjuvant therapy
- Where
- 65 sites in United States, South Africa
- Volunteers
- 216 people
- Sponsor
- Gynecologic Oncology Group
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer
- Trial name
- NCT00007813
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma
S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003416
- Testing
- filgrastim, recombinant interferon alfa, dexamethasone
- Where
- 84 sites in United States
- Volunteers
- 9 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.